IL133305A0 - Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome - Google Patents

Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome

Info

Publication number
IL133305A0
IL133305A0 IL13330598A IL13330598A IL133305A0 IL 133305 A0 IL133305 A0 IL 133305A0 IL 13330598 A IL13330598 A IL 13330598A IL 13330598 A IL13330598 A IL 13330598A IL 133305 A0 IL133305 A0 IL 133305A0
Authority
IL
Israel
Prior art keywords
protein inhibitor
treating protein
binding interruptor
inhibitor syndrome
exogenous protein
Prior art date
Application number
IL13330598A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL133305A0 publication Critical patent/IL133305A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
IL13330598A 1997-06-20 1998-06-19 Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome IL133305A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (fr) 1997-06-20 1998-06-19 Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques

Publications (1)

Publication Number Publication Date
IL133305A0 true IL133305A0 (en) 2001-04-30

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13330598A IL133305A0 (en) 1997-06-20 1998-06-19 Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome

Country Status (25)

Country Link
US (1) US20020119151A1 (fr)
EP (1) EP1034001B1 (fr)
JP (1) JP2002504910A (fr)
KR (1) KR100567998B1 (fr)
CN (2) CN1261285A (fr)
AT (1) ATE272408T1 (fr)
AU (1) AU733062B2 (fr)
BG (1) BG64436B1 (fr)
BR (1) BR9810755A (fr)
CA (1) CA2294138A1 (fr)
CZ (1) CZ295805B6 (fr)
DE (1) DE69825473T2 (fr)
EA (1) EA002512B1 (fr)
EE (1) EE9900587A (fr)
ES (1) ES2226152T3 (fr)
HK (1) HK1031825A1 (fr)
HU (1) HUP0002048A3 (fr)
IL (1) IL133305A0 (fr)
IS (1) IS2097B (fr)
NO (1) NO996274L (fr)
NZ (1) NZ502051A (fr)
PT (1) PT1034001E (fr)
SK (1) SK285962B6 (fr)
TR (1) TR199903141T2 (fr)
WO (1) WO1998058672A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
EP2149585B1 (fr) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Procédés d'utilisation d'anticorps monoclonaux antagonistes anti-CD40
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (fr) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Procédés et compositions permettant d'inhiber la neddylation des protéines
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l

Also Published As

Publication number Publication date
JP2002504910A (ja) 2002-02-12
HK1031825A1 (en) 2001-06-29
CA2294138A1 (fr) 1998-12-30
SK285962B6 (sk) 2007-12-06
IS5274A (is) 1999-11-26
DE69825473T2 (de) 2005-08-04
CZ458899A3 (cs) 2000-04-12
EP1034001A1 (fr) 2000-09-13
EA200000059A1 (ru) 2000-08-28
KR100567998B1 (ko) 2006-04-07
CN1651071A (zh) 2005-08-10
EA002512B1 (ru) 2002-06-27
BG64436B1 (en) 2005-02-28
IS2097B (is) 2006-04-12
NO996274D0 (no) 1999-12-17
KR20010013964A (ko) 2001-02-26
HUP0002048A2 (hu) 2000-10-28
EP1034001B1 (fr) 2004-08-04
TR199903141T2 (xx) 2000-09-21
PT1034001E (pt) 2004-12-31
WO1998058672A1 (fr) 1998-12-30
CZ295805B6 (cs) 2005-11-16
BR9810755A (pt) 2000-08-15
AU733062B2 (en) 2001-05-03
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
CN1261285A (zh) 2000-07-26
DE69825473D1 (de) 2004-09-09
ATE272408T1 (de) 2004-08-15
NO996274L (no) 2000-02-18
SK180399A3 (en) 2000-06-12
BG104092A (en) 2000-10-31
NZ502051A (en) 2001-04-27
AU8153698A (en) 1999-01-04
ES2226152T3 (es) 2005-03-16
US20020119151A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
IL133305A0 (en) Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
AU2002360592A1 (en) Inhibitors of hepatitis c virus
WO2001024816A3 (fr) Compositions et procedes d'inhibition de la caseomorphine et de la gluteomorphine
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
UA72909C2 (en) Cinnamide derivatives useful in the treatment of inflammatory and immune diseases, a composition containing such derivatives and a method for the preparation of cinnamide derivatives
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
EP0992243A4 (fr) Agent prophylactique/therapeutique
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
WO1998018818A3 (fr) Nouveaux inhibiteurs de l'hepatite b
EP0331803A3 (fr) Médicament pour empêcher l'attaque et pour traiter la migraine au moyen d'un inhibiteur ace
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
IL114808A (en) Combinations of protease inhibitors for the treatment of hiv infection and aids
WO2004017902A3 (fr) Ubiquitine et molecules liees a l'ubiquitine destinees au traitement et a la prevention d'une activation nuisible du systeme immunitaire
AUPO347396A0 (en) Synergistic gold-containing compositions
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
EP0663211A4 (fr) Agent de prevention et de traitement des desordres de la muqueuse de l'appareil digestif.